Background <p>Boosting the performance of chimeric antigen receptor T (CAR-T) cell therapy in solid tumors may provide a substantial advantage for patients with cancer. Recognizing the vital role of the nuclear factor of activated T cells (NFAT) in T cell function, we hypothesized the strategic regulation of NFAT activity by targeting c-Jun N-terminal kinases (JNK) can bolster the tumor-eradicating potential…
JNK knockdown enhances CAR-T cell cytotoxicity through elevated NFATc1-dependent transcription in preclinical ovarian cancer models
Journal for ImmunoTherapy of Cancer | | Kuhlmann, C. J., Jepson, C. E., Blucas, M. T., Suleiman, F. M., Manda, A., Kamata, Y. N., Kamata, M.
Topics: ovarian-cancer, immunotherapy, chemotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer